Tin tức & Cập nhật
Xem bài viết Nội tiết
Xem
Chỉ hiển thị Multimedia

Tirzepatide: A winning weight-loss therapy for nondiabetic, obese adults
25 Jun 2022
bởiRoshini Claire Anthony
Non-diabetic overweight or obese adults experienced a greater reduction in weight and cardiometabolic measures with the addition of tirzepatide to their lifestyle interventions, findings of the SURMOUNT-1 trial showed.
25 Jun 2022

SGLT2is reduce serious hyperkalaemia risk in T2D, CKD patients
23 Jun 2022
bởiAudrey Abella
Sodium-glucose cotransporter 2 inhibitors (SGLT2is) consistently reduced the risk of serious hyperkalaemia (serum potassium [K+] ≥6.0 mmol/L) without increasing the risk of hypokalaemia (serum K+ ≤3.5 mmol/L) in individuals with type 2 diabetes (T2D) at high cardiovascular (CV) risk, or in those with chronic kidney disease (CKD), a meta-analysis has shown.
23 Jun 2022






